Product logins

Find logins to all Clarivate products below.


Matthew Jewkes

SVP and Head of AI Product Transformation

Matthew Jewkes is SVP and Head of AI Product Transformation at Clarivate. In this role, Matth ew is broadly responsible for the development of proprietary Artificial Intelligence platform capabilities, Artificial Intelligence guidance and advisory, and transformative Artificial Intelligence applications in Clarivate products and services, focusing on Life Sciences & Healthcare.

Matthew joined Clarivate through its acquisition of MotionHall, where he was co-founder and CTO. At MotionHall, he oversaw the development of proprietary technology and guided the development of a comprehensive digital twin of the global biopharmaceutical industry. This model leverages terabytes of proprietary industry data, massively indexed public data sets, and worked on proprietary deep learning neural networks as well as other computational methodologies.

Matthew has led at the forefront of multiple significant transitions in software, from introduction of the iPhone to advanced cryptographic methods, and now the rapidly emerging capabilities of AI technologies.

He is a strong advocate for corporate social responsibility, customer success and employee success and a champion for the benefit of our customers and the patients they serve.

Matthew studied Computer Science at Dalhousie University.

Related resources

为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇 为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
Blog March 2, 2026
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
AI/机器学习 GLP-1 临床试验 交易 药政法规 衰老生物学
为何更方便的给药方式并未获得支付方青睐 为何更方便的给药方式并未获得支付方青睐
Blog February 26, 2026
为何更方便的给药方式并未获得支付方青睐
医疗保险 定价 市场准入 真实世界数据 美国市场
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规